Log In
BCIQ
Print this Print this
 

PL225B

  Manage Alerts
Collapse Summary General Information
Company Piramal Enterprises Ltd.
DescriptionOral insulin-like growth factor-1 (IGF-1) receptor inhibitor
Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)
Mechanism of ActionInsulin-like growth factor-1 (IGF-1) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced refractory solid tumors
Regulatory Designation
PartnerMerck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today